Open access
Jul 2026
Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas
Abstract Background This multi-institutional phase I trial aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicities, pharmacokinetics, and preliminary antitumor activity of berubicin (WP744 or RTA744), designed to cross the blood–brain barrier, in patients with primary brain cancers. Methods Thirty...
C. Conrad, S. Hsu, N. Thapar et al.
· Neuro-Oncology Advances · 0 citations